Stock Price & Analysis

Based on the provided data and current market status (closed), here's a concise analysis for ABT stock:

Technical Analysis

The stock closed at $113.48 on Friday with a regular market decline of -0.38%. The RSI at 48.68 indicates a neutral momentum, neither overbought nor oversold. The price is hovering around its 20-day moving average of $113.44, suggesting sideways consolidation.

Fundamental Catalysts Abbott Laboratories is scheduled to report Q4 2024 earnings on January 22, 2025 (Wednesday) before market opens. Analysts expect:

• EPS of $1.34, up 12.6% year-over-year
• Revenue of $11.02 billion, up 7.64% year-over-year

Near-term Outlook The stock appears to be in a holding pattern ahead of earnings. Key technical levels to watch:

• Support: $111.43 (Fibonacci S1)
• Resistance: $114.44 (Fibonacci R1)

Recommendation HOLD. With earnings coming up in 2 days, it's prudent to wait for the results before making any position changes. The current technical setup suggests range-bound trading between support and resistance levels.

Based on the provided data and market analysis, here is the price prediction for ABT stock in 2025:

ABT stock is expected to reach $125-130 by end of 2025, representing a 10-15% upside from current price of $113.48. The prediction is driven by strong fundamentals in medical devices segment showing 11% growth, continued market leadership in diagnostics, and expected earnings growth of 10.1% year-over-year to $5.14 in fiscal 2025.

The technical analysis shows ABT is currently trading near key support level of $111.43 with next resistance at $114.44 based on Fibonacci levels. The RSI of 48.68 indicates neutral momentum, while MACD at -0.52 suggests slight bearish pressure in near-term.

The S1 support level for ABT Stock is $111.85 ,The R1 resistant level for ABT Stock is $123.16.

As of the end of day on 2025-01-24, the price of ABT Stock was $125.05.

The target price for ABT Stock according to analyst rating is 134.47, with the highest price target at 149.00 and the lowest at 117.00. Analysts have a Strong Buy rating on ABT Stock overall.

The market cap of ABT is $216.9B.

Based on the provided financial data and recent market trends, here's a comprehensive analysis of ABT's valuation:

Valuation Analysis ABT currently trades at a P/E ratio of 34.57x (Q3 2024), which is significantly above its historical average, indicating potential overvaluation. The EV/EBITDA multiple of 20.08x also suggests premium pricing compared to industry standards.

Financial Performance

• Revenue shows steady growth: Q1 $9.96B → Q2 $10.38B → Q3 $10.64B
• Net margin improvement: Q1 12.29% → Q2 12.55% → Q3 15.48%
• Gross margin expansion: Q1 50.58% → Q2 51.10% → Q3 51.82%

Key Valuation Metrics

• P/S ratio: 4.84x
• P/B ratio: 4.97x
• Dividend yield: 1.93%

Balance Sheet Strength

• Current ratio remains stable at 1.60x
• Debt-to-equity ratio at 37.42%, indicating conservative leverage
• Strong cash flow generation with improving operating metrics

Conclusion ABT appears overvalued at current levels based on:

1. Premium valuation multiples above historical averages
2. Despite strong operational performance, current pricing has exceeded fundamental justification
3. Market is pricing in significant future growth that may be challenging to achieve
4. Trading at substantial premium to peers despite similar growth profiles

Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.

Based on the provided data and context, I'll analyze ABT's potential price for 2030. Here's a concise 3-sentence projection:

Abbott Laboratories (ABT) stock is projected to reach $165-175 by 2030, representing a compound annual growth rate of approximately 6.5% from current levels, driven by its strong position in diagnostics market, continued leadership in medical devices, and robust growth in emerging markets. The company's consistent dividend growth history as a Dividend King, coupled with its strategic investments in healthcare technology and infrastructure development, provides a solid foundation for this growth trajectory. While near-term headwinds exist including industry-wide challenges such as margin pressure and labor shortages, Abbott's diversified revenue streams across nutrition, established pharmaceuticals, diagnostics, and medical devices segments position it well for long-term growth through 2030.

ABT has a total of 114000 employees.